Investors are starting to bet big on psychedelic medicine

August 25, 2020 Articles 7:21 pm

Just weeks after the U.S. Food and Drug Administration approved approved Johnson & Johnson’s ketamine-like nasal spray for depression, a group of European technology investors just got together for the largest-ever private financing round for a psychedelic medicine biotech company, ATAI.

 

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit